©2024 Stanford Medicine
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
Not Recruiting
Trial ID: NCT00726323
Purpose
This clinical study is being conducted at multiple sites to determine the best confirmed
response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell
carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic
forms; subjects with either classification will be accepted into this study.
Official Title
A Phase II Study of the c-MET RTK Inhibitor XL880 in Subjects With Papillary Renal-Cell Carcinoma
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- Histologically confirmed diagnosis of PRC with metastatic disease or bilateral
multifocal renal tumors localized to kidneys. Measurable disease, ECOG performance
status of
- Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.
Exclusion Criteria:
- Radiation to >/=25% of bone marrow within 14 days of GSK1363089, more than 1 prior
anti-cancer therapy, received prior treatment with a c-met inhibitor, brain
metastases,
- Any uncontrolled intercurrent illness,
- Pregnant or breastfeeding,
- HIV positive
Intervention(s):
drug: foretinib (formerly GSK1363089 or XL880)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
6507361252